(12) **Translation of European patent specification**

(11) **NO/EP 3209656 B1**

(19) NO

NORWAY

(51) Int Cl.

C07D 403/12 (2006.01)
A61K 31/4045 (2006.01)
A61P 29/00 (2006.01)
A61P 37/00 (2006.01)
C07D 209/18 (2006.01)
C07D 401/04 (2006.01)
C07D 401/06 (2006.01)
C07D 401/12 (2006.01)
C07D 403/04 (2006.01)
C07D 403/10 (2006.01)
C07D 413/04 (2006.01)
C07D 417/04 (2006.01)
C07D 471/04 (2006.01)
C07D 487/04 (2006.01)
C07D 487/10 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.08.24
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.04.01
(86)	European Application Nr.	15790407.9
(86)	European Filing Date	2015.10.23
(87)	The European Application's Publication Date	2017.08.30
(30)	Priority	2014.10.24, US, 201462068225 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, USA
(72)	Inventor	AHMAD, Saleem, c/o Bristol-Myers Squibb CompanyRoute 206&Province Line Road, Princeton, New Jersey 08543, USA TINO, Joseph A., c/o Bristol-Myers Squibb CompanyRoute 206&Province Line Road, Princeton, New Jersey 08543, USA MACOR, John E., 55 Commanders Drive, Washington Crossing, PA 18977, USA TEBBEN, Andrew J., c/o Bristol-Myers Squibb CompanyRoute 206&Province Line Road, Princeton, New Jersey 08543, USA GONG, Hua, c/o Bristol-Myers Squibb CompanyRoute 206&Province Line Road, Princeton, New Jersey 08543, USA LIU, Qingjie, c/o Bristol-Myers Squibb CompanyRoute 206&Province Line Road, Princeton, New Jersey 08543, USA BATT, Douglas G., c/o Bristol-Myers Squibb CompanyRoute 206&Province Line Road, Princeton, New Jersey 08543, USA NGU, Khehyong, c/o Bristol-Myers Squibb CompanyRoute 206&Province Line Road, Princeton, New Jersey 08543, USA WATTERSON, Scott Hunter, c/o Bristol-Myers Squibb CompanyRoute 206&Province Line Road, Princeton, New Jersey 08543, USA GUO, Weiwei, 32 Pagoda Court, Lawrenceville, NJ 08648, USA BEAUDOIN BERTRAND, Myra, c/o Bristol-Myers Squibb CompanyRoute 206&Province Line Road, Princeton, New Jersey 08543, USA

(74) Agent or Attorney TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **INDOLE CARBOXAMIDES COMPOUNDS USEFUL AS KINASE INHIBITORS**

(56) References Cited:
WO-A1-2008/144253
WO-A1-2014/210255
WO-A1-2013/157022

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. En forbindelse med formel (I):



(I)

eller et salt eller solvat derav, hvor:

X er CR_4;

A er:



eller



;

Q_2 er -C(O)CH=CH_2, -C(O)CH=$CHCH_2N(CH_3)_2$, -C(O)C≡CR_7, -C(O)C≡C(fenyl), -C(O)C≡C(C_{1-3} hydroksyalkyl), -C(O)C≡$CSi(CH_3)_3$, eller -$S(O)_2$CH=CH_2;

R_1 er H, -CH_3, -CF_3 eller fenyl substituert med null eller 1 R_{12};

R_2 er H, -CH_3, syklopropyl eller fenyl substituert med null eller 1 R_{12}, forutsatt at minst en av R_1 og R_2 er -CH_3;

R_3 er F eller Cl;

R_4 er H eller F;

R_7 ved hver forekomst er uavhengig H, C_{1-4} alkyl eller syklopropyl; og

R_{12} er F, Cl, -CN, -CF_3 eller C_{1-3} alkoksy.

2. Forbindelse ifølge krav 1 eller et salt eller solvat derav, hvor:

R_1 er CH_3 og R_2 er CH_3.

3. Forbindelse ifølge krav 1 eller et salt eller solvat derav, hvor:
R_3 er F.

4. Forbindelse ifølge krav 1 eller et salt eller solvat derav, hvor:
R_7 ved hver forekomst er H eller C_{1-2} alkyl.

5. Forbindelse ifølge krav 1 som har strukturen:



.

6. Forbindelse ifølge krav 1 eller et salt eller solvat derav, hvor forbindelsen er valgt fra: (*S*)-4-(3-acrylamidopiperidin-1-yl)-5-fluor-2,3-dimetyl-1*H*-indol-7-karboksamid; (*S*)-4-(3-acrylamidopyrrolidin-1-yl)-5-fluor-2,3-dimetyl-1*H*-indol-7-karboksamid; (*S*)-5-fluor-2,3-dimetyl-4-(3-(*N*-methylbut-2-ynamido)piperidin-1-yl)-1*H*-indol-7-karboksamid; (*S*)-5-fluor-2,3-dimetyl-4-(3-(pent-2-ynamido)piperidin-1-yl)-1*H*-indol-7-karboksamid; (*S*)-5-fluor-2,3-dimetyl-4-(3-(*N*-methylpent-2-ynamido)piperidin-1-yl)-1*H*-indol-7-karboksamid; (*S*)-5-fluor-4-(3-(hex-2-ynamido)piperidin-1-yl)-2,3-dimetyl-1*H*-indol-7-karboksamid; (*S*)-4-(3-(*N*-ethylbut-2-ynamido)piperidin-1-yl)-5-fluor-2,3-dimetyl-1*H*-indol-7-karboksamid; (*S*)-4-(3-(but-2-ynamido)pyrrolidin-1-yl)-5-fluor-2,3-dimetyl-1*H*-indol-7-karboksamid; (*S*)-4-(3-(3-cyklopropylpropiolamido)piperidin-1-yl)-5-fluor-2,3-dimetyl-1*H*-indol-7-karboksamid; (*S*)-5-fluor-2,3-dimetyl-4-(3-(vinylsulfonamido)piperidin-1-yl)-1*H*-indol-7-karboksamid; (*S*)-4-(3-(N-cyclopropylbut-2-ynamido)piperidin-1-yl)-5-fluor-2,3-dimetyl-1*H*-indol-7-karboksamid; 4-(4-(but-2-ynoyl) piperazin-1-yl)-5-fluor-2,3-dimetyl-1*H*-indol-7-karboksamid; 4-(4-acryloylpiperazin-1-yl)-5-fluor-2,3-dimetyl-1*H*-indol-7-karboksamid; 4-(1-akryloyl-1,2,5,6-tetrahydropyridin-3-yl)-5-fluor-2,3-dimetyl-1*H*-indol-7-karboksamid; (*RS*)-4-(1-acryloylpiperidin-3-yl)-5-fluor-2,3-dimetyl-1*H*-indol-7-karboksamid; 4-(1-acryloylpiperidin-3-yl)-5-fluor-2,3-dimetyl-1*H*-indol-7-karboksamid, enkle enantiomerer; (*RS*)-4-(1-(but-2-ynoyl)piperidin-3-yl)-5-fluor-2,3-dimetyl-1*H*-indol-7-karboksamid; og (*S*)-4-(3-(but-2-ynamido)piperidin-1-yl)-5-fluor-2,3-dimetyl-1*H*-indol-7-karboksamid.

7. Farmasøytisk sammensetning omfattende en forbindelse ifølge et hvilket som helst av kravene 1-6 eller et farmasøytisk akseptabelt salt eller solvat derav; og en farmasøytisk akseptabel bærer.

8. Forbindelse ifølge et hvilket som helst av kravene 1-6 eller et farmasøytisk akseptabelt salt eller solvat derav, for bruk i terapi.

9. Forbindelse ifølge et hvilket som helst av kravene 1-6 eller et farmasøytisk akseptabelt salt eller solvat derav, for bruk i terapi for behandling av autoimmun sykdom eller kronisk inflammatorisk sykdom.

10. Forbindelse for bruk ifølge krav 9, hvor nevnte autoimmun sykdom eller kronisk inflammatorisk sykdom er valgt fra systemisk lupus erytematose (SLE), revmatoid artritt, multippel sklerose (MS) og Sjögrens syndrom.